Jump Financial LLC Takes Position in Vaxcyte, Inc. $PCVX

Key Points

• Jump Financial LLC acquired 100,100 shares of Vaxcyte, Inc. for approximately $3,780,000, representing a 0.08% ownership stake at the end of the first quarter.
• Vaxcyte's stock price has declined by 5.7%, with a current trading price of $30.45, while its 12-month range fluctuates between $27.66 and $121.06.
• Vaxcyte missed quarterly earnings expectations, reporting a loss of ($1.22) EPS against a consensus estimate of ($1.12), leading analysts to project a negative earnings per share of -4.21 for the current year.

Jump Financial LLC acquired a new position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 100,100 shares of the company's stock, valued at approximately $3,780,000. Jump Financial LLC owned approximately 0.08% of Vaxcyte as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. AlphaQuest LLC bought a new position in Vaxcyte in the first quarter worth approximately $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Vaxcyte in the first quarter worth approximately $35,000. Parallel Advisors LLC grew its stake in Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock worth $61,000 after purchasing an additional 1,071 shares in the last quarter. IFP Advisors Inc grew its stake in Vaxcyte by 376.4% in the first quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock worth $62,000 after purchasing an additional 1,306 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in Vaxcyte by 10.9% in the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock worth $112,000 after purchasing an additional 293 shares in the last quarter. Institutional investors own 96.78% of the company's stock.

Vaxcyte Stock Performance

Vaxcyte stock traded up $0.02 during mid-day trading on Friday, reaching $30.79. 944,896 shares of the company were exchanged, compared to its average volume of 1,511,927. The business has a fifty day moving average of $33.34 and a 200 day moving average of $42.17. The firm has a market cap of $4.00 billion, a P/E ratio of -7.49 and a beta of 1.04. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same period in the prior year, the firm posted ($1.10) earnings per share. Sell-side analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Analysts Set New Price Targets

Separately, Cowen reissued a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.